AbbVie and Genmab will engage global regulatory authorities regarding their joint development efforts.
8 reports, 3 independent
Updated Sep 8
Gone quiet
Reached 3 outlets in its first 24 hours
- Reports
- 8
- Developments
- 4
- Repetition
- 62%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
AbbVie and Genmab will engage global regulatory authorities regarding their joint development efforts.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.AbbVie and Genmab's joint development of a lymphoma drug has failed clinical trials.1 source
Successful Phase 3 trials for lymphoma and product efficacy gained for acute migraine.1 source
- A collaboration between AbbVie, Genmab, and Nxera Pharma has seen joint trial success, leading to potential milestone payments and favorable opinions from the European Commission.Sub-event
AbbVie and Genmab plan to engage global regulatory authorities.1 source
Keep exploring
The entities involved
Related events
- AbbVie and Abbott Laboratories are large healthcare companies whose corporate histories are linked by a major split that occurred in 2013.
- AbbVie, Eli Lilly, and Merck are broadening their therapeutic reach.
- AbbVie and others are managing drug exclusivity, seeking next-gen immunology pipeline growth, and competing for market share.
- Bristol-Myers Squibb and AbbVie secured regulatory approval for a therapy in the US.
- AbbVie reached an agreement for a drug in Canada.